By: Benzinga
UPDATE: Stifel Nicolaus Raises PT to $118 on Allergan on Solid 2013 Outlook
Stifel Nicolaus maintained Allergan (NYSE: AGN ) with a Buy rating and raised the price target from $110.00 to $118.00. Stifel Nicolaus noted, "2013 guidance was robust, with product sales of $5.9-6.2bn (Consensus at high end of range) and EPS between $4.75-4.83 (15-17% growth, Consensus $4.74). Notably, guidance excluded
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here